Acelyrin Beheer

Beheer criteriumcontroles 0/4

De CEO Acelyrin is Mina Kim, benoemd in May2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde $ 116.97K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.1 jaar en 2.2 jaar.

Belangrijke informatie

Mina Kim

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.1yrs
Gemiddelde ambtstermijn bestuur	2.2yrs

Recente managementupdates

Recent updates

CEO

Mina Kim (50 yo)

less than a year

Tenure

Ms. Mina Kim joined and served as a Chief Legal Officer at Zymergen, Inc. since January 2020 until August 2022 and also serves as its Corporate Secretary. She served as the Chief Legal and Administrative O...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mina Kim	CEO & Director	less than a year	geen gegevens	0.025% $ 117.0k
Gilbert Labrucherie	CFO & Chief Business Officer	1.2yrs	geen gegevens	0.047% $ 222.4k
Tyler Marciniak	Head of Investor Relations & Communications	2.5yrs	geen gegevens	geen gegevens
K. Murugan	Chief Legal Officer	no data	geen gegevens	0.00050% $ 2.4k
Kelly Chow	Chief People Officer	no data	geen gegevens	geen gegevens
Suzy Buckhalter	Senior Director of Finance & Accounting	no data	geen gegevens	geen gegevens
Kenneth Lock	Chief Commercial Officer	1.3yrs	geen gegevens	geen gegevens
Shephard Mpofu	Chief Medical Officer	1.1yrs	geen gegevens	geen gegevens
Patricia Turney	Chief Technical Operations Officer	less than a year	geen gegevens	geen gegevens

1.1yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SLRN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mina Kim	CEO & Director	less than a year	geen gegevens	0.025% $ 117.0k
Bruce Cozadd	Independent Chairman	2.7yrs	US$390.49k	0% $ 0
Beth Seidenberg	Independent Director	4.1yrs	US$349.51k	0.060% $ 283.8k
Lynn Tetrault	Independent Director	less than a year	US$482.26k	0% $ 0
C. Machado	Independent Director	3.6yrs	US$402.20k	0.015% $ 69.4k
Alan Colowick	Independent Director	3yrs	geen gegevens	geen gegevens
Dawn Svoronos	Independent Director	1.9yrs	US$376.67k	0.015% $ 70.9k
Daniel Becker	Independent Director	2.2yrs	US$351.09k	0.0030% $ 14.2k
Henry Gosebruch	Independent Director	1.7yrs	US$1.02m	0.050% $ 236.5k

2.2yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SLRN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.2 jaar), wat duidt op een nieuw bestuur.

Acelyrin Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Acelyrin, Inc. Announces CEO Changes

Acelyrin, Inc., Annual General Meeting, Jun 07, 2024

Chief Medical Officer notifies of intention to sell stock

Co-Founder recently sold US$119k worth of stock

Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

High number of new and inexperienced directors

Recent updates

Acelyrin, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Acelyrin, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch

New minor risk - Shareholder dilution

Price target decreased by 47% to US$12.00

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa

Acelyrin, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024

New major risk - Revenue and earnings growth

Price target decreased by 8.3% to US$22.17

Acelyrin, Inc. Announces CEO Changes

Acelyrin, Inc. to Report Q1, 2024 Results on May 13, 2024

Acelyrin, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis

Acelyrin, Inc. Announces Long-Term 32-Week Data from the Phase 2B Trial of Izokibep in Hidradenitis Suppurativa

New minor risk - Insider selling

Co-Founder recently sold US$119k worth of stock

Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

High number of new and inexperienced directors

Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Acelyrin, Inc

Acelyrin, Inc. Appoints Lynn Tetrault to Board of Directors

Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program

Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program

Equity Alert: Rosen Encourages Acelyrin, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Equity Alert: Rosen Encourages Acelyrin, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Acelyrin, Inc. Appoints Patricia Turney as Chief Technical Operations Officer

Acelyrin, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Financial data availability

Acelyrin, Inc. Appoints Shephard Mpofu as Senior Vice President of Development

Acelyrin, Inc. Appoints Gil Labrucherie as Full Time Chief Financial Officer

New major risk - Revenue and earnings growth

ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer

New major risk - Financial position

Acelyrin, Inc. has completed an IPO in the amount of $540 million.

No independent directors

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd